---
title: "GeneDx - CW27 | 8-K: FY2025 Q4 Revenue: USD 120.99 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276605061.md"
datetime: "2026-02-23T13:18:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276605061.md)
  - [en](https://longbridge.com/en/news/276605061.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276605061.md)
generator: "portal-rs"
---

# GeneDx - CW27 | 8-K: FY2025 Q4 Revenue: USD 120.99 M

Revenue: As of FY2025 Q4, the actual value is USD 120.99 M.

EPS: As of FY2025 Q4, the actual value is USD -0.61.

EBIT: As of FY2025 Q4, the actual value is USD -13.72 M.

### Segment Revenue

#### Fourth Quarter 2025 (Q4 2025)

-   Total Revenue: $121.0 million .
-   GeneDx Revenue: $119,492 thousand .
-   Other Revenue: $1,497 thousand .
-   Growth in exome and genome revenue: 32% (42% excluding a 2024 one-time benefit) .

#### Full Year 2025 (FY 2025)

-   Total Revenue: $427.5 million, which was within the previous guidance of $425 to $428 million .
-   GeneDx Revenue: $423,088 thousand .
-   Other Revenue: $4,451 thousand .
-   Growth in exome and genome revenue: 54% (58% excluding a 2024 one-time benefit), within the previous guidance of 53% to 55% .

#### Full Year 2024 (FY 2024)

-   GeneDx Revenue: $302,293 thousand .
-   Other Revenue: $3,157 thousand .

### Operational Metrics

#### Adjusted Gross Margin (non-GAAP)

-   Q4 2025: 71% .
-   FY 2025: 71%, within the previous guidance of 70% to 71% .
-   Q4 2024: 70.3% .
-   FY 2024: 65.1% .

#### Adjusted Net Income (non-GAAP)

-   Q4 2025: $4.4 million .
-   FY 2025: $41.8 million .
-   Q4 2024: $17,453 thousand .
-   FY 2024: $9,405 thousand .

#### Net (Loss) Income (GAAP)

-   Q4 2025: - $17,666 thousand .
-   Q4 2024: $5,438 thousand .
-   FY 2025: - $21,021 thousand .
-   FY 2024: - $52,286 thousand .

#### Gross Profit (GAAP)

-   Q4 2025: $84,268 thousand .
-   Q4 2024: $66,205 thousand .
-   FY 2025: $298,173 thousand .
-   FY 2024: $194,397 thousand .

#### Gross Margin (GAAP)

-   Q4 2025: 69.6% .
-   Q4 2024: 69.2% .
-   FY 2025: 69.7% .
-   FY 2024: 63.6% .

### Cash and Unique Metrics

#### Cash on Hand

-   Cash on Hand: $172 million .

#### Growth in Exome and Genome Volume

-   Q4 2025 YoY: 34.3% .
-   FY 2025 YoY: 30.5%, meeting the previous guidance of at least 30% .

#### Exome and Genome Volume FY ‘22 - ‘25 CAGR

-   47% .

#### Exome and Genome Revenue FY ‘22 - ‘25 CAGR

-   61% .

### Outlook / Guidance

GeneDx projects full-year 2026 revenue between $540 to $555 million, with exome and genome revenue and volume growth expected to be 33% to 35% . The company anticipates an adjusted gross margin of at least 70% and positive adjusted net income for the year . Exome and genome test result volume is guided to be 128k to 131k for FY 2026 .

### Related Stocks

- [WGSWW.US](https://longbridge.com/en/quote/WGSWW.US.md)

## Related News & Research

- [TECHNICALS-US oil may extend gains to $100.76](https://longbridge.com/en/news/298528617.md)
- [Brent holds above $100 as tanker attacks deepen supply fear](https://longbridge.com/en/news/298520925.md)
- [Stellantis CEO highlights diverging US and global strategies](https://longbridge.com/en/news/298636085.md)
- [Last Minute Thought: Buy or Sell Oracle Stock as Earnings Loom? Here’s What Scotiabank Thinks](https://longbridge.com/en/news/298627363.md)
- [Elon Musk Says Anthropic’s 15% US GDP Growth Scenario Will 'Certainly Be True’ Once Humanoid Robots Reach Volume Production](https://longbridge.com/en/news/298554997.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**